We have an excellent track record for producing spin-out companies from applied research with a significant role in the development of new products and services.
Our Spin out companies also contribute to the development and vitality of the region through new jobs and revenue creation.
A number of these companies are going from strength to strength, notably in the biotechnology sector and include:
Advanced Electric Machines’ unique, low cost traction motor technology is designed to drive tomorrow's hybrid, range extended and electric commercial vehicles. The technology, designed specifically for commercial vehicles, delivers excellent performance in a robust package.
CEO: James Widmer
Alcyomics is a UK based unique pre-clinical service provider using Skimune®, non-artificial human skin explants for safety and efficacy assessment of novel compounds and drugs. Its mission is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies and to extend its technologies for use in the chemical and cosmetic industries.
CEO: Anne Dickinson
Atelerix offers a transformative hydrogel technology for the storage and transport of viable cells including stem cells and cell-based assays at ambient temperatures. This overcomes the barriers presented by the current need for cryo-shipping as it is simple, cell-friendly and offers immediate access to stem cell therapies.
CEO: Mick McLean
Changing Health provides digital services aimed at people suffering from, or at risk of, Type 2 diabetes. It provides access to a range of digital health education articles and interactive activities on diet and exercise along with personal telephone access to a specialist lifestyle behaviour change coach.
CEO: John Grumitt
Demuris is a drug discovery and development company employing state-of-the-art platform technologies in natural product discovery, design and production. The starting point for Demuris’ portfolio of new drug development often lies in a unique collection of Actinomycete bacteria. These organisms can manipulate the behaviour of surrounding organisms, including bacteria, fungi, plants and animals.
CEO: Jeff Errington
e-Therapeutics plc accelerates drug discovery through a novel view of disease networks. By combining biological expertise and a powerful computer-based platform, the company creates and analyses network models of disease to identify likely proteins that could effectively be disrupted to treat the disease.
CEO: Ray Barlow
Newcells Biotech’s expertise is in the production of induced pluripotent stem cells and their differentiation into a wide range of reliable and reproducible cell and tissue types. The company aims to provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells and services.
CEO: Mike Nicholds
Demand for genetic variation testing in patients is rapidly growing driven by advances in medical genetics and personalised medicine. Testing can determine a patient’s biological characteristics in order to select the most effective therapy regime. NewGene is a pioneer in developing, validating and delivering molecular diagnostics using the latest high throughput sequencing and genotyping technologies.
CEO: Angela Silmon
Video Enhanced Observation (VEO) provides training and staff development though use of live-tag video on accessible devices. VEO’s video-tagging system allows users to timestamp their video. This enhances the quality and convenience of review, whilst generating valuable statistics on activity. The system also includes an app and user-portal.
CEO: Paul Miller